Burning Rock Dx’s Post

Key Insight Sharing An article titled 'Tumor biomarkers for diagnosis, prognosis, and targeted therapy' has been published in the journal Signal Transduction and Targeted Therapy. This comprehensive review explores the discovery and development of tumor biomarkers, the classification of tumor biomarkers based on tissue origin, and their applications in clinical cancer management. The article also discusses the limitations and challenges in this field, along with insights and perspectives on transforming these challenges into opportunities. Read more: https://lnkd.in/gDuEZu54

Exciting News from Burning Rock Dx! Burning Rock has achieved outstanding results in recent proficiency tests, demonstrating our expertise in advanced diagnostic technologies. We successfully passed the 2024 proficiency tests initiated by the National Center for Clinical Laboratories (NCCL), including "2024 High-Throughput Sequencing Test for Tumor Free DNA Mutation", "BRAF Mutation Test", "EGFR Mutation Test" and "KRAS Mutation Test". Additionally, we excelled in evaluations by the European Molecular Genetics Quality Network (EMQN) for DNA sequencing and the College of American Pathologists (CAP) for RNA sequencing and Multigene Tumor Panels. In these seven proficiency tests, we analyzed 28 samples covering key tumor driver genes such as BRAF, EGFR, KRAS, NRAS, PIK3CA, ERBB2 (HER2), KIT, and PDGFRA using our products OncoScreen®-WES, OncoCompass® Target, OncoRNA, and LungCure. The results matched the official standards perfectly, showcasing the exceptional sensitivity, specificity, and stability of our tumor diagnostic products. #PrecisionMedicine #BurningRockDx

Burning Rock Dx Spotlight: OnconCompass®Target The study published in Journal of Thoracic Oncology at Feb. 2020, aimed to assess the impact of harboring 5′-ALK on the efficacy of crizotinib. The study is the first to confirm that presence of nonreciprocal/reciprocal ALK translocation was predictive for worse PFS and greater likelihood of baseline brain metastases in patients with ALK-rearranged NSCLC who received first-line crizotinib. This study uses OnconCompass®Target to sequence DNA isolated from tissue or blood samples obtained from all the patients. 🔗 Read more: https:https://lnkd.in/gZW3247E #NSCLC #BurningRockDx

Key Insight Sharing Recently, One article that delved into the boundaries of NGS (Next-Generation Sequencing) in clinical applications. In this article, the author emphasized the natural advantages of NGS, including its ability to explore the unknown and provide comprehensive analysis. As Burning Rock Dx, we will continue to explore the potential of NGS in clinical applications and work towards bridging the gap between research and practice. We are committed to balancing the advantages and limitations of NGS, ultimately paving the way for its successful integration into clinical science and practice. #BurningRockDx #NGS #PrecisionMedicine #ClinicalApplications

A groundbreaking study published in Cell Reports Medicine highlights a new hope for EGFR-mutant NSCLC patients. The study provides supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC. Notably, ctDNA was used as a biomarker to dynamically monitor minimal residual disease, aiding in the identification of patients responding to the treatment. This study, supported by Burning Rock's personalized MRD product, brPROPHET, underscores the importance of preoperative MRD testing in guiding dynamic monitoring and study design for patients with tumor gene mutations. 🔗 Read more: https://lnkd.in/gUDxmraw #LungCancer #CellReportsMedicine #BurningRock

Today, we celebrate the powerful bond between sports, wellness, and healthcare. At Burning Rock Dx, we are dedicated to advancing human health and recognize the pivotal role of physical activity in promoting overall well-being. 🏅🌍 International Olympic Day is a reminder of the positive impact that athletic endeavors have on individual health and community resilience. It highlights values like determination, teamwork, and perseverance—values that align with our mission to enhance lives through innovative diagnostics and personalized healthcare solutions. On this special day, let's embrace the Olympic spirit to promote healthy living and emphasize the importance of integrating sports into healthcare. Together, we can champion a healthier and more active world. Happy International Olympic Day from all of us at Burning Rock Dx! #OlympicDay

Burning Rock Dx Spotlight: OncoCompass® Target   Introducing a Reliable and Evidence-based ctDNA Testing Solution   We are proud to introduce OncoCompass® Target, a CE-certified liquid biopsy tool that sets the standard in ctDNA testing. Backed by rigorous performance validations and extensive research, OncoCompass® Target delivers exceptional accuracy and specificity, ensuring reliable results for targeted therapy and cancer management.   Key Highlights: · Comprehensive Validation: Proven high sensitivity, specificity, and reproducibility. · Extensive Research: Over 90 papers published since 2020. · Clinical Utility: Supports targeted therapy, immuno-oncology, and germline specific gene analysis. Stay tuned as we dive deeper into some of the groundbreaking research supporting OncoCompass® Target. For more information, feel free to reach out to us at PBD@brbiotech.com.   #LiquidBiopsy #ctDNA #BurningRockDx

Our colleague Chun (Michael) Chen , PharmD, is presenting today at the Immuno-Oncology hubXchange conference in Boston! 🎤✨ His keynote topic is: "Exploring the potential: harnessing ctDNA MRD in immune-oncology treatment for solid tumors." Our team members will be at the conference all day, eager to engage with all attendees. Looking forward to discussing the latest advancements in immuno-oncology! If you're at the event, be sure to connect with us! #ImmunoOncology #BurningRockDx #ctDNA #MRD

Happy Father's Day from Burning Rock Dx! This Father's Day, let's prioritize the health and well-being of our dads. With OverC™ Multi-Cancer Detection Blood Test, we offer a revolutionary early detection for 5 cancer types. One tube of blood can make a big difference. 🩺 Health Tips for Dad: › Stay active: Enjoy physical activities like walking, golf, or gardening. › Eat well: Focus on a balanced diet with fruits, vegetables, lean proteins, and whole grains. › Regular check-ups: Ensure regular health check-ups and screenings. › Mental well-being: Remember the importance of mental health and seek support when needed. Celebrate this special day by ensuring your dad's health and happiness! #FathersDay #EarlyCancerDetection #BurningRockDx

We are excited to share that Chun (Michael) Chen, PharmD, from Burning Rock Dx, will be presenting at the Immuno-Oncology Xchange run by hubXchange Join us for his keynote presentation titled: "Exploring the potential: harnessing ctDNA MRD in immune-oncology treatment for solid tumors." 🗓 Date: June 18, 2024 🕒 Time: 8:30 - 9:00 AM 📍 Woburn Hilton Hotel, Boston MA 01801 In addition, our talented team members ，Shawn A. , Alex Brand and Liliang Jin will also be attending the conference. This is a fantastic opportunity to connect and discuss the latest advancements in immuno-oncology. #ImmunoOncology #CancerResearch #BurningRockDx #ctDNA #MRD